Generali Asset Management SPA SGR Has $8.24 Million Stock Holdings in Zoetis Inc. $ZTS

Key Points

• Generali Asset Management SPA SGR increased its stake in Zoetis Inc. by 5.1%, now owning 52,816 shares valued at approximately $8.24 million.
• Various institutional investors have actively adjusted their holdings in Zoetis, with notable increases from Sound Income Strategies LLC and Canoe Financial LP, indicating strong interest in the company.
• Analysts have mixed ratings on Zoetis, with a consensus rating of "Hold" and a target price averaging around $196.71, reflecting cautious optimism among market experts.

Generali Asset Management SPA SGR boosted its holdings in shares of Zoetis Inc. (NYSE:ZTS - Free Report) by 5.1% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 52,816 shares of the company's stock after acquiring an additional 2,562 shares during the period. Generali Asset Management SPA SGR's holdings in Zoetis were worth $8,237,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Sound Income Strategies LLC increased its stake in Zoetis by 54.3% during the 2nd quarter. Sound Income Strategies LLC now owns 432 shares of the company's stock worth $67,000 after purchasing an additional 152 shares in the last quarter. Strs Ohio acquired a new position in shares of Zoetis in the first quarter valued at approximately $22,891,000. Canoe Financial LP increased its position in shares of Zoetis by 859.0% during the second quarter. Canoe Financial LP now owns 13,369 shares of the company's stock worth $2,085,000 after acquiring an additional 11,975 shares in the last quarter. Tandem Investment Advisors Inc. raised its holdings in shares of Zoetis by 100.3% during the first quarter. Tandem Investment Advisors Inc. now owns 395,626 shares of the company's stock worth $65,140,000 after acquiring an additional 198,089 shares during the period. Finally, Soros Capital Management LLC lifted its position in Zoetis by 32.0% in the 1st quarter. Soros Capital Management LLC now owns 17,441 shares of the company's stock valued at $2,872,000 after acquiring an additional 4,230 shares in the last quarter. 92.80% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of equities analysts have issued reports on the company. Leerink Partnrs cut Zoetis from a "strong-buy" rating to a "hold" rating in a report on Thursday, July 17th. Argus reiterated a "buy" rating and set a $190.00 price objective on shares of Zoetis in a report on Tuesday, September 9th. Leerink Partners lowered Zoetis from an "outperform" rating to a "market perform" rating and dropped their target price for the company from $180.00 to $155.00 in a research report on Thursday, July 17th. Stifel Nicolaus cut Zoetis from a "buy" rating to a "hold" rating and cut their target price for the company from $165.00 to $160.00 in a research note on Wednesday, June 18th. Finally, Piper Sandler raised their price target on shares of Zoetis from $210.00 to $215.00 and gave the stock an "overweight" rating in a research note on Monday, August 11th. Four analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company. According to data from MarketBeat.com, Zoetis currently has a consensus rating of "Hold" and a consensus target price of $196.71.

Zoetis Price Performance

NYSE:ZTS opened at $143.45 on Wednesday. Zoetis Inc. has a 52-week low of $139.34 and a 52-week high of $196.55. The company has a market cap of $63.58 billion, a P/E ratio of 24.69, a P/E/G ratio of 2.28 and a beta of 0.90. The company has a debt-to-equity ratio of 1.05, a quick ratio of 1.04 and a current ratio of 1.76. The stock's 50-day simple moving average is $148.98 and its 200 day simple moving average is $154.11.

Zoetis (NYSE:ZTS - Get Free Report) last issued its quarterly earnings results on Tuesday, August 5th. The company reported $1.76 EPS for the quarter, beating the consensus estimate of $1.62 by $0.14. The firm had revenue of $2.46 billion during the quarter, compared to analysts' expectations of $2.41 billion. Zoetis had a return on equity of 56.90% and a net margin of 27.83%.The business's quarterly revenue was up 4.2% compared to the same quarter last year. During the same period in the prior year, the firm posted $1.56 earnings per share. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. As a group, sell-side analysts forecast that Zoetis Inc. will post 6.07 EPS for the current fiscal year.

Zoetis Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, December 2nd. Investors of record on Friday, October 31st will be paid a $0.50 dividend. The ex-dividend date of this dividend is Friday, October 31st. This represents a $2.00 annualized dividend and a dividend yield of 1.4%. Zoetis's dividend payout ratio (DPR) is currently 34.42%.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.

Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.